Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AMC Entertainment

GameStop

The investment thesis for these high-flying stocks no longer holds water.

It's Time to Book Profits in These 3 Ultra-Popular Stocks

Pfizer

They could result in a broader market for Pfizer's vaccine.

3 Areas Where Pfizer Is Crushing Moderna

Are Booster Doses of Pfizer's and Moderna's COVID Vaccines on the Way?

BioNTech SE

Co-Diagnostics

Novavax

Vaxart

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Why Coronavirus Stocks Are Zooming Higher Today

Moderna, known for its success in the COVID-19 vaccine, has entered the big league with its addition to the S&P 500 Index.

Moderna Soars on Inclusion to S&P 500: ETFs in Focus

Chevron

Goldman Sachs

Peloton

The Dow was down more than 750 points Monday morning.

Is This the Long-Awaited Stock Market Crash?

A Japanese health ministry panel has backed Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine for emergency use in children aged between 12 to 17 years, paving the way for final approval by the ministry in the coming days. The panel recommended lowering the current age restriction of 18 and older without conducting an additional clinical trial in the country.

Japan Health Ministry Supports Lowering Minimum Age For Moderna's COVID-19 Vaccine To 12 Years

There's no guarantee that the biotech's share price will continue climbing.

Moderna's Joining the S&P 500: What's Next for the Hot Vaccine Stock?

Moderna and Novavax are leading Biotech companies who are expected to be major competitors in the COVID-19 vaccine market moving forward. While Moderna has a strong head start in the market in 2021, Novavax's impending entry is likely to offer stiff competition.

Moderna And Novavax: Competing For Global Domination In The Vaccines Market

AbbVie

Biogen

There are important things to watch with each of these stocks.

4 Large-Cap Healthcare Stocks You'll Want on Your Radar for the Second Half of 2021

Even more gains could lie ahead for the biotech's investors.

Why Moderna Stock Soared 23% This Week

Annovis Bio

Good news! There's a way to avoid this portfolio pain -- and it doesn't involve avoiding the whole sector.

Here's Why The Biotech Stocks You Bought Keep Going Down

Moderna Inc. (NASDAQ:MRNA)became the latest addition to the S&P 500 Index. The company will officially join the list on 27th July to start enjoying the benefits of belonging to an elite class of companies.

As Moderna joins the S&P 500, is it time to buy?

Moderna, Inc (NASDAQ: MRNA) gapped up 6.64% Friday morning after it was announced the company will join the S&P 500 beginning July 21. The pharmaceutical company, which created a COVID-19 vaccine, will replace Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN).

Moderna Options Traders Mixed On S&P 500 Inclusion

Find out why a big index move is so interesting for investors.

This Nasdaq Vaccine Stock Just Got a Big Boost -- and Another Nasdaq Vaccine Stock Deserves the Credit

Apple

Ambev

Bank of America

Ford Motor Company

General Electric

Virgin Galactic

Wish

We're about halfway through trading today and that means it's time for a market update. Today's focus is the 10 most active stocks on Friday.

Market Update: The 10 Most Active Stocks on Friday

The company joins the S&P 500 index next week.

Why Moderna Stock Just Jumped 10%

Moderna's (MRNA) success with its COVID-19 vaccine, mRNA-1273, continues to drive the stock. The company crosses $100-billion in market capitalization and will join the S&P 500 soon.

Moderna (MRNA) Set to Join S&P 500 Riding on Vaccine Success

Moderna (MRNA) stock is on the rise Friday as the company prepares to join the S&P 500 next week replacing Alexion Pharmaceuticals (ALXN). The post MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500 appeared first on InvestorPlace.

MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500

The first week of earnings season wraps up with major indices closely tracking the bond market in Wall Street's version of “follow the leader.” Earnings absolutely matter, but right now the Fed's policies are maybe a bigger influence.

Vaccine Stocks Climb After Moderna Added To S&P 500, With BioNTech Also Up

Moderna, the biotech that became a household name with its Covid-19 vaccine, is getting the ultimate Wall Street validation: It's being added to the S&P 500 index.

Moderna gets the ultimate Wall Street validation: It's being added to the S&P 500

Pharmaceutical name Moderna Inc (NASDAQ:MRNA) is surging this morning, up 7.8% at $279.95 at last check, after earlier nabbing an all-time high of $280.50.

MRNA Surges to Record High on Plans to Join S&P 500

Alexion Therapeutics, which is set to be acquired by AstraZeneca, will be replaced by Moderna in the market-cap weighted index.

Moderna spikes 8% to record highs after it is selected to be added to S&P 500

The stock price of Moderna Inc (NASDAQ: MRNA) increased by over 8% pre-market. This is why it happened.

MRNA Stock Increases Over 8% Pre-Market: Why It Happened

COVID-19 vaccine leader Moderna is joining the big leagues.

News for Moderna Stock (MRNA)